Shareholders Equity and Capital Stock (Details 4) $ in Thousands |
12 Months Ended |
|---|---|
|
Dec. 31, 2020
USD ($)
shares
| |
| Number of unvested units | shares | 1,404,962 |
| Remaining life (years) | 1 year 4 months 24 days |
| Aggregate Intrinsic Value | $ | $ 1,123,969 |
| November 13, 2022 [Member] | |
| Number of unvested units | shares | 737,553 |
| Remaining life (years) | 1 year 10 months 24 days |
| Aggregate Intrinsic Value | $ | $ 590,042 |
| November 05, 2021 [Member] | |
| Number of unvested units | shares | 667,409 |
| Remaining life (years) | 9 months 18 days |
| Aggregate Intrinsic Value | $ | $ 533,927 |
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|